Logotipo del repositorio
Logotipo del repositorio
 

Guía de práctica clínica para glomerulonefritis membranosa

Vista sencilla de ítem
datacite.alternateIdentifier
datacite.rightshttp://purl.org/coar/access_right/c_abf2spa
dc.contributor.authorAroca Martínez, Gustavo José
dc.contributor.authorConde, Juan Carlos
dc.contributor.authorCastillo, Luis
dc.contributor.authorAlmendrales Escobar, Lisneth
dc.contributor.authorDomínguez Vargas, Alex Alfredo
dc.contributor.authorMora Hernández, María Auxiliadora
dc.contributor.authorSilva Díaz, Diana Carolina
dc.date.accessioned2022-10-25T16:27:47Z
dc.date.available2022-10-25T16:27:47Z
dc.date.issued2017
dc.description.abstractLa nefropatía membranosa (NM) constituye una de las causas más frecuentes de síndrome nefrótico en sujetos adultos y ancianos, mientras que en niños y adolescentes es rara. La incidencia se sitúa en unos 5-10 casos por millón de población y año. Es una enfermedad causada por antígenos específicos y anticuerpos dirigidos contra ellos, que se depositan en la cara externa de la membrana basal glomerular. Clásicamente se han diferenciado dos grandes subtipos de NM, las NM primarias o idiopáticas (NMI) y las NM secundarias. En las primeras, el antígeno responsable era desconocido y no existía una enfermedad o fármaco relacionado con el desencadenamiento del cuadro, mientras que en las segundas el proceso era causado por enfermedades sistémicas, tumores, infecciones o fármacos diversos. En los últimos años se ha logrado identificar el antígeno podocitario contra el que se desencadena el proceso de formación de anticuerpos (autoinmunidad) en un 60-75 % de los casos de NMI.spa
dc.format.mimetypepdfspa
dc.identifier.isbn9789585430402
dc.identifier.urihttps://hdl.handle.net/20.500.12442/11232
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGlomerulonefritisspa
dc.subjectNefrologíaspa
dc.subjectGlomerulonefritis – Patologíaspa
dc.subjectRiñones – Enfermedadesspa
dc.titleGuía de práctica clínica para glomerulonefritis membranosaspa
dc.type.driverinfo:eu-repo/semantics/bookspa
dc.type.spaLibrospa
dcterms.bibliographicCitationDebiec H, Guigonis V, Mougenot B y cols. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346:2053-2060. [Pubmed]eng
dcterms.bibliographicCitationBeck LH Jr, Bonegio RG, Lambeau G y cols. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21 [Pubmed]eng
dcterms.bibliographicCitationStanescu HC, Arcos-Burgos M, Medlar A y cols. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:616-626 [Pubmed]eng
dcterms.bibliographicCitationPrunotto M, Carnevali ML, Candiano G y cols. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21:507-519 [Pubmed]eng
dcterms.bibliographicCitationDebiec H, Lefeu F, Kemper MJ y cols. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101-2110 [Pubmed]eng
dcterms.bibliographicCitationSchulze M, Brunckhorst R, Frei U, y cols. Elevated urinary excretion of the C5b-9 membrane attack complex of complement indicates progression of membranous nephropathy. J Am Soc Nephrol 1992; 3:614-622.eng
dcterms.bibliographicCitationGlassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003; 23:324-32.[Pubmed]eng
dcterms.bibliographicCitationCattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001; 59:1983-1994. [Pubmed]eng
dcterms.bibliographicCitationFulladosa X, Praga M, Segarra A y cols. Glomerulonefritis membranosa. Nefrología 2007; 27 (Supl 2): 70-86spa
dcterms.bibliographicCitationPraga M, Andres A, Hernandez E y cols. Tubular dysfunction in nephrotic syndrome: incidence and prognostic implications. Nephrol Dial Transplant 1991; 6:683-688. [Pubmed]eng
dcterms.bibliographicCitationJennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous nephropathy. Kidney Int 1983; 24:377-385 [Pubmed]eng
dcterms.bibliographicCitationYoshimoto K, Yokoyama H, Wada T y cols. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int 2004; 65:148-153. [Pubmed]eng
dcterms.bibliographicCitationSchieppati A, Mosconi L, Perna A y cols. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329:85-89 [Pubmed]eng
dcterms.bibliographicCitationDonadio JJV, Torres VE, Velosa JA y cols. Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 1988; 33:708-715 [Pubmed]eng
dcterms.bibliographicCitationPolanco N, Gutierrez E, Covarsí A y cols. Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. J Am Soc Nephrol 2010; 21:697-704. [Pubmed]eng
dcterms.bibliographicCitationdu Buf-Vereijken PWG, Branten AJW, Wetzels JFM. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46:1012-1029. [Pubmed]eng
dcterms.bibliographicCitationTorres A, Dominguez-Gil B, Carreño A y cols. Conservative versus inmunosuppresive treatment of patients with idiopathic membranous nephropathy and deteriorating renal function. Kidney Int 2002; 61:219-227. [Pubmed]eng
dcterms.bibliographicCitationPolanco N, Gutierrez E, Rivera F y cols. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant 2012; 27:231-234 [Pubmed]eng
dcterms.bibliographicCitationCattran, DC, Pei Y, Greenwood C y cols. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51 (3): 901?907 [Pubmed]eng
dcterms.bibliographicCitationVan den Brand JA, Hofstra J, Wetzels JFM. Low-molecular weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6 (12): 2846?2853 [Pubmed]eng
dcterms.bibliographicCitationBranten AJ, du Buf-Vereijken PW, Klasen IS y cols. Urinary excretion of ?2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16 (1): 169?174[Pubmed]eng
dcterms.bibliographicCitationHofstra J, Beck LH, Wetzels JFM y cols. Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6 (6): 1286?1291 [Pubmed]eng
dcterms.bibliographicCitationBeck LH, du Buf-Vereijken PW, Klasen IS y cols. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22 (8): 1543?1550 [Pubmed]eng
dcterms.bibliographicCitationKidney Disease:Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Supplements 2012; 2: 139274. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdfeng
dcterms.bibliographicCitationPonticelli C, Zuchelli P, Passerini P y cols. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48:1600- 1604 [Pubmed]eng
dcterms.bibliographicCitationPonticelli, C, Altieri, P, Scolari, F y cols. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444-450 [Pubmed]eng
dcterms.bibliographicCitationJha V, Ganquli A, Saha TK y cols. A randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18:1899-1904 [Pubmed]eng
dcterms.bibliographicCitationCattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989; 320:210-215. [Pubmed]eng
dcterms.bibliographicCitationCattran, DC, Appel, GB, Hebert, LA y cols. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001; 59:1484-1490. [Pubmed]eng
dcterms.bibliographicCitationPraga M, Barrio V, Fernández-Juárez G, Luño J for the Grupo Español de estudio de la nefropatía membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71:924-930.[Pubmed]eng
dcterms.bibliographicCitationMathieson PW. Proteinuria and immunity-an overstated relationship?. N Engl J Med 2008; 359:2492-2494.[Pubmed]eng
dcterms.bibliographicCitationSegarra A, Praga, Ramos N. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4:1083- 1088. [Pubmed]eng
dcterms.bibliographicCitationBomback AS, Derebail VK, McGregor JG. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:734-74 [Pubmed]eng
dcterms.bibliographicCitationRuggenenti P, Cravedi P, Chianca A. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1416-1425 [Pubmed]eng
dcterms.bibliographicCitationChoi MJ, Eustace JA, Gimenez LF. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098-1114 [Pubmed]eng
dcterms.bibliographicCitationDussol B, Morange S, Burtey S. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008; 52 (4):699-705 [Pubmed]eng
dcterms.bibliographicCitationSegarra A, Amoedo ML, Martínez García JM y cols. Efficacy and safety of ¿rescue teraphy¿ with mycophenolate mofetil in resistant primary glomerulonephritis-A multicenter study. Nephrol Dial Transplant 2007; 22:1351-1360. [Pubmed]eng
dcterms.bibliographicCitationRauen T, Michaelis A, Floege J y cols. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009; (6):637-42 [Pubmed]eng
dcterms.bibliographicCitationPonticelli C, Passerini P, Salvadori M y cols. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropin hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47:233-240. [Pubmed]eng
dcterms.bibliographicCitationHowman A, Chapman TL, Langdon MM y cols. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744-751. [Pubmed]eng
dcterms.bibliographicCitationCattran DC, Reich HN, Beanlands HJ y cols. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23:2247-2253. [Pubmed]eng
dcterms.bibliographicCitationTroyanov S, Wall CA, Miller JA y cols. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66:1199-1205 [Pubmed]eng
dcterms.bibliographicCitationSprangers B, Lefkowitz GI, Cohen SD y cols. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5:790-7 [Pubmed]eng
oaire.versioninfo:eu-repo/semantics/publishedVersionspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
23.57 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Libros

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca